Bridgebio Pharma Inc
BridgeBio Pharma (BBIO) is a clinical-stage biopharmaceutical company focused on developing precision medicines for genetic disorders and selected cancers. With a market capitalisation of about $10.39bn, BridgeBio advances a diversified pipeline of small molecules and biologics, including several programmes in late-stage or registrational trials. Its value proposition centres on targeted therapies designed for specific genetic drivers, but progress is highly dependent on clinical trial outcomes and regulatory approvals. The company often uses partnerships and licensing to share risk and access expertise, while remaining R&D-intensive with limited commercial revenues to date. For investors this means potential high upside if key programmes succeed, counterbalanced by binary clinical risk, extended development timelines and possible financing needs. This is general educational information and not personalised financial advice; consider your objectives and tolerance for risk before acting.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying Bridgebio Pharma's stock with a target price of $71.94, indicating potential growth.
Financial Health
Bridgebio Pharma is performing well with strong revenue, cash flow, and profit margins.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring BBIO
Pharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketMASH Stocks: Could Roche's Deal Spark More M&A?
Roche's $3.5 billion acquisition of 89bio for its liver disease drug highlights the growing MASH treatment market. This deal creates a potential tailwind for other biopharmaceutical companies developing therapies for liver and metabolic conditions.
Published: September 21, 2025
Explore BasketBeyond The Patent Cliff: Pharma's New Growth Engines
AbbVie raised its profit outlook, proving it can thrive after its blockbuster Humira faced competition. This creates an investment opportunity in resilient pharmaceutical companies that are successfully launching new drugs to replace older ones.
Published: August 1, 2025
Explore BasketPioneers In Rare Disease Therapy
The FDA's approval of PTC Therapeutics' drug for the rare disorder PKU marks a significant advancement in metabolic disease treatment. This event creates an investment opportunity by highlighting the growth potential of other biopharmaceutical companies specializing in therapies for rare genetic conditions.
Published: July 29, 2025
Explore BasketChina's Biopharma Innovators: The Next Global Partnership Wave
Following GSK's major licensing deal with China's Jiangsu Hengrui, a new investment theme is emerging around Chinese pharmaceutical innovators. This theme focuses on other Chinese biopharma companies that are likely to attract similar global partnerships, driving value through their advanced drug development pipelines.
Published: July 28, 2025
Explore BasketPharma's Next Big Deal
This carefully curated group of stocks features promising biotech companies with valuable drug pipelines. These smaller firms could become the next targets for lucrative partnerships or acquisitions by pharmaceutical giants, similar to Glenmark's recent $2 billion deal with AbbVie.
Published: July 11, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Precision medicines pipeline
Multiple programmes target genetically defined diseases and cancers, offering potential step-changes if trials succeed — though outcomes can be binary.
Milestone-driven value
Share price movements often hinge on trial readouts and approvals, creating catalysts but also short-term volatility.
Partnerships and reach
Collaborations and licensing help de‑risk development and expand capabilities, yet the company remains R&D-heavy and may need capital to progress programmes.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
AbbVie Inc.
Abbvie is a research-based biopharmaceutical company that develops and markets advanced therapies to address complex medical conditions.
Amgen Inc.
Amgen is a global biotechnology company that focuses on discovering, developing and commercializing treatments for unmet medical needs.
ADMA BIOLOGICS INC
Develops products to treat immune deficiencies and chronic diseases.
